Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing
- Publication of the study in the Journal of Surgery enhances the credibility of CellerateRX Surgical Powder.
- The study demonstrates the potential of CellerateRX to be used in surgeries across multiple specialties.
- The results of the study support the benefits of using CellerateRX as documented in previous studies.
- None.
FORT WORTH, TX, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that the Journal of Surgery has published a retrospective study on CellerateRX® Surgical Powder (“CellerateRX”) titled “Activated Collagen Powder Significantly Reduces Surgical Site Infections in Patients Undergoing Elective Surgery”.
Zach Fleming, Sanara’s CEO stated, “This study demonstrates that the use of CellerateRX can have a significant impact on surgical patients’ outcomes by promoting wound healing and helping to prevent surgical site infections. We believe these results align with our mission of improving outcomes while lowering costs and support the benefits of using CellerateRX as documented in previous studies. Based in part on this study, we also believe that CellerateRX can be used in surgeries across multiple specialties to help prevent surgical site infections and positively impact outcomes.”
About the Study and Key Results
- Retrospective study of 5,335 patients undergoing elective surgeries over four years. More than a quarter of the patients received CellerateRX in evaluation of clean (
76% ) or clean contaminated (24% ) cases. - Surgical specialties included general, surgical oncology, orthopedic, vascular, neurosurgery, cardiothoracic, plastic and gynecology.
- The use of activated collagen (CellerateRX) in patients undergoing elective surgery resulted in a
59% reduction in surgical site infection rates. This reduction was most pronounced in the clean cases with a69% decrease in surgical site infection rates.
Dr. Ryan Nowrouzi and Dr. Samir Awad, the lead investigators of the study, commented on the significance of the research, stating “Surgical site infections can lead to morbidity, mortality, and increased healthcare costs. This study demonstrates that activated collagen (CellerateRX) can be safely used in elective surgical procedures to promote wound healing of incisions with an associated decrease in the rate of surgical site infections following surgery.”
Click Here to the view the full Journal of Surgery article on this study. The study was partially funded by a grant from a subsidiary of the Company.
About CellerateRX® Surgical Powder
CellerateRX® is Type I bovine activated collagen and contains no additives. It is indicated for use in the management of acute and chronic wounds, including surgical wounds, partial- and full-thickness wounds, traumatic wounds, venous stasis ulcers, arterial ulcers, diabetic ulcers, and first- and second-degree burns.
About Sanara MedTech Inc.
With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE™ Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution and HYCOL® Hydrolyzed Collagen. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy products and the oxygen delivery system segment of the wound and skincare markets.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the ability of CellerateRX to be used in surgeries across multiple specialties, the development of new products, the timing of commercialization of our products, the regulatory approval process and expansion of the Company’s business in telehealth and wound care. These items involve risks, contingencies and uncertainties such as the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
FAQ
What is the latest announcement from Sanara MedTech Inc. (NASDAQ: SMTI)?
What are the key findings of the study on CellerateRX Surgical Powder?
Who is the CEO of Sanara MedTech Inc. (NASDAQ: SMTI)?
What does the CEO believe about the study results?
Where is Sanara MedTech Inc. based?
